Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.

Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis W, Moul J, Fahey A.

Med Care. 2004 Mar;42(3):239-50.

PMID:
15076823
2.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
3.

Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis.

Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD.

Am J Mens Health. 2010 Sep;4(3):189-206. doi: 10.1177/1557988309353934. Epub 2010 May 18. Review.

PMID:
20483872
4.

An analysis of watchful waiting for clinically localized prostate cancer.

Steinberg GD, Bales GT, Brendler CB.

J Urol. 1998 May;159(5):1431-6. Review.

PMID:
9554328
5.

Prostate cancer in black men of African-Caribbean descent.

Kleier JA.

J Cult Divers. 2003 Summer;10(2):56-61. Review.

PMID:
14508926
6.

Critical review: is watchful waiting a viable management option for older men with prostate cancer?

Bailey DE Jr, Wallace M.

Am J Mens Health. 2007 Mar;1(1):18-28. doi: 10.1177/1557988306294161. Review.

PMID:
19482780
7.

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CaPSURE Investigators..

J Urol. 2004 Apr;171(4):1393-401. Review.

8.

Update on watchful waiting for prostate cancer.

Allaf ME, Carter HB.

Curr Opin Urol. 2004 May;14(3):171-5. Review.

PMID:
15069308
9.

Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review.

Schmid HP, Adolfsson J, Aus G.

Eur Urol. 2001 Nov;40(5):488-94. Review.

PMID:
11752854
10.

Prostate cancer in the African American: is this a different disease?

Powell IJ.

Semin Urol Oncol. 1998 Nov;16(4):221-6. Review.

PMID:
9858329
11.

Racial and ethnic disparities in the receipt of cancer treatment.

Shavers VL, Brown ML.

J Natl Cancer Inst. 2002 Mar 6;94(5):334-57. Review.

PMID:
11880473
12.

The role of watchful waiting in the management of localized prostate cancer.

Chodak GW.

J Urol. 1994 Nov;152(5 Pt 2):1766-8. Review.

PMID:
7933235
13.

Diagnosis and treatment of prostate cancer.

Naitoh J, Zeiner RL, Dekernion JB.

Am Fam Physician. 1998 Apr 1;57(7):1531-9, 1541-2, 1545-7. Review.

14.

The epidemiology of prostate cancer in the United States.

Brawley OW, Barnes S.

Semin Oncol Nurs. 2001 May;17(2):72-7. Review.

PMID:
11383246
15.

Prostate cancer in black and white Americans.

Reddy S, Shapiro M, Morton R Jr, Brawley OW.

Cancer Metastasis Rev. 2003 Mar;22(1):83-6. Review.

PMID:
12716039
16.

Prostate cancer and black men.

Brawley OW.

Semin Urol Oncol. 1998 Nov;16(4):184-6. Review.

PMID:
9858323
17.

Prostate cancer treatment outcome in blacks and whites: a summary of the literature.

Alexander GA, Brawley OW.

Semin Urol Oncol. 1998 Nov;16(4):232-4. Review.

PMID:
9858331
18.

Prostate cancer and psychosocial concerns in African American men: literature synthesis and recommendations.

Pierce R, Chadiha LA, Vargas A, Mosley M.

Health Soc Work. 2003 Nov;28(4):302-11. Review.

PMID:
14679709
19.

Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy.

Messing EM, Thompson I Jr.

Urol Clin North Am. 2003 Nov;30(4):687-702, viii. Review.

PMID:
14680308
20.

Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.

Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN.

Crit Rev Oncol Hematol. 2010 Jan;73(1):68-91. doi: 10.1016/j.critrevonc.2009.09.005. Review.

PMID:
19836968

Supplemental Content

Support Center